Titans of the automotive, banking, and technology industries have spoken out in recent days against President Donald Trump’s move to block arrivals from seven Muslim-majority nations.

But the pharmaceutical sector, which relies disproportionately on immigrant labor, has been almost universally silent — perhaps in a bid to avoid rousing Trump’s ire before a crucial meeting Tuesday morning at the White House.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • To the author and Ed: Where did “But the pharmaceutical sector, which relies disproportionately on immigrant labor…” this come from? All foreign born working in US are green card holders as they want to become citizens or are citizens.

    Pharma in the developed countries have to change their model. Their model of inventing new drugs (generics included) and abandoning them to low tax countries or developing countries has been the holy grail.

    Industry needs to think differently and their buying and selling of legislatures has to change. Glory days of legalized buying legislature may be history.

    PBMs and Medicare should negotiate and instill best mfg. technology to lower costs. It is practiced in every other manufacturing and should be done for pharma also.

  • “he has advocated legalizing the importation of medicines from nations where prices are lower.”

    The problem with this is that each country’s drug prices do not exist in a vacuum. Part of the reason Pharma companies can cut deals for other countries is because they make up for it in the U.S. pricing. I’m certainly not saying that’s an ideal situation, but it complicates matters.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy